Page 23 - Let them speak Towards a patient reported outcome measure set for

General introduction
https://www.fda.gov/drugs/development-approval-process-drugs/fda-patient-focused-drug-
development-guidance-series-enhancing-incorporation-patients-voice-medical2024.
39. Hurley EN, Ellaway CJ, Johnson AM, Truong L, Gordon R, Galettis P, et al. Efficacy and safety
of cannabidivarin treatment of epilepsy in girls with Rett syndrome: A phase 1 clinical trial.
Epilepsia. 2022;63(7):1736–47.
40. Glaze DG, Neul JL, Percy A, Feyma T, Beisang A, Yaroshinsky A, et al. A double-blind,
randomized, placebo-controlled clinical study of trofinetide in the treatment of Rett syndrome.
Pediatric neurology. 2017;76:37–46.
41. Djukic A, Holtzer R, Shinnar S, Muzumdar H, Rose SA, Mowrey W, et al. Pharmacologic
treatment of Rett syndrome with glatiramer acetate. Pediatric neurology. 2016;61:51–7.
42. Kang S, Jones A, Shaffer RC, Erickson CA, Schmitt LM. Developing improved outcome
measures in FXS: Key stakeholder feedback. Research in developmental disabilities.
2023;137:104502.
43. Greenberg KK, Schwartz AE, Kramer JM. Adoption of patient‐reported outcome measures
with youth with intellectual/developmental disabilities: Contextual influences and practice
patterns. Child: Care, Health and Development. 2021;47(4):501–8.
44. Benjamin K, Vernon MK, Patrick DL, Perfetto E, Nestler-Parr S, Burke L. Patient-reported
outcome and observer-reported outcome assessment in rare disease clinical trials: an ISPOR
COA emerging good practices task force report. Value in Health. 2017;20(7):838–55.
45. Maguire S, Davison J, McLaughlin M, Simms V, Bunting B. Exploring the psychometric properties
of self‐report instruments used to measure health‐related quality of life and subjective
wellbeing of adolescents with intellectual disabilities: A Consensus‐based Standards for
the Selection of Health Measurement Instruments (COSMIN) systematic review. Journal of
Applied Research in Intellectual Disabilities. 2023;36(5):899–915.
46. Robertson J, Hatton C, Emerson E, Baines S. Prevalence of epilepsy among people with
intellectual disabilities: a systematic review. Seizure. 2015;29:46–62.
47. Agar G, Brown C, Sutherland D, Coulborn S, Oliver C, Richards C. Sleep disorders in rare genetic
syndromes: a meta-analysis of prevalence and profile. Molecular autism. 2021;12:1–17.
48. Zeidan J, Fombonne E, Scorah J, Ibrahim A, Durkin MS, Saxena S, et al. Global prevalence of
autism: A systematic review update. Autism research. 2022;15(5):778–90.
49. Dodd S, Clarke M, Becker L, Mavergames C, Fish R, Williamson PR. A taxonomy has been
developed for outcomes in medical research to help improve knowledge discovery. Journal of
clinical epidemiology. 2018;96:84–92.
50. Terwee CB, Zuidgeest M, Vonkeman HE, Cella D, Haverman L, Roorda LD. Common patient-
reported outcomes across ICHOM Standard Sets: the potential contribution of PROMIS(R).
BMC Med Inform Decis Mak. 2021;21(1):259.
51. Oude Voshaar M, Terwee CB, Haverman L, van der Kolk B, Harkes M, van Woerden CS, et al.
Development of a standard set of PROs and generic PROMs for Dutch medical specialist care:
Recommendations from the Outcome-Based Healthcare Program Working Group Generic
PROMs. Quality of Life Research. 2023:1595–605.
52. Terwee CB, Ahmed S, Alhasani R, Alonso J, Bartlett SJ, Chaplin JE, et al. Comparable Real-
World Patient-Reported Outcomes Data Across Health Conditions, Settings, and Countries:
The PROMIS International Collaboration. NEJM Catalyst Innovations in Care Delivery.
2024;5(9):CAT. 24.0045.
1
21